Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol

With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet